Nov 25 (Reuters) - The U.S. Food and Drug Administration
on Tuesday extended its review of Ascendis Pharma's ( ASND )
therapy for children with a rare genetic disorder that causes
dwarfism, the company said.
The health regulator extended its review by 3 months to
February 28, 2026.